Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling. (PubMed, J Clin Pharmacol) - Sep 20, 2026 - "The predicted small reductions in apixaban and rivaroxaban exposures (AUCinf <10%) are not expected to be clinically relevant since a 20% no-effect boundary is typically used to determine the clinical impact of a DDI. The PBPK model predictions are consistent with the apixaban and rivaroxaban labels, which do not warn against co-administration with weak or moderate CYP3A inducers, such as suzetrigine."
Journal • Pain
|
|
Bo Feng; Brian Hare; Elizabeth Lakota; Guanyu Wang; Guiqing Liang; Licong Jiang
|